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ABSTRACT
Introduction. Smoking is the number one preventable cause of death 
in the United States. Under the Affordable Care Act, Kansas Med-
icaid covers all seven FDA-approved smoking cessation therapies. 
However, it is estimated only 3% of Kansas Medicaid smokers use 
treatment compared to the national estimate of 10%. The objective 
is to determine systemic barriers in place that prevent optimal uti-
lization of Medicaid smoking cessation benefits among KU Medical 
Center Internal Medicine patients.
Methods. For this quality improvement project, a population of 169 
Kansas Medicaid smokers was identified who had been seen at the KU 
Internal Medicine Clinic from January 1, 2015 - February 16, 2016. 
Phone surveys were completed with 62 individuals about smoking 
status, interest in using smoking cessation treatment options, and 
awareness of Medicaid coverage of treatment.
Results. Of the 62 respondents, 24 (39%) were prescribed pharma-
cotherapy and 41 (66%) were interested in using smoking cessation 
treatment. There were eight who had quit smoking. Of the remain-
ing 54 smokers, 31 (57%) were unaware that Medicaid would cover 
pharmacotherapy. Of 24 participants who received a prescription for 
pharmacotherapy, 13 (54%) were able to fill the prescription at no cost 
using the Medicaid benefit.
Conclusion. The majority of respondents were interested in using 
smoking cessation treatment, yet three main barriers existed to using 
Medicaid smoking cessation benefits: physicians not prescribing 
treatment to patients, patients not aware of Medicaid coverage, and 
inadequate pharmacy filling. Improved physician and patient aware-
ness of Medicaid coverage will facilitate more patients receiving 
smoking cessation therapy and ultimately quitting smoking. 
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INTRODUCTION
 Smoking is the leading preventable cause of death in the United 
States.1 Medicaid enrollees are twice as likely to be smokers as the 
general population, 32% vs 17%,2 which places a large financial 
burden on the Medicaid program. The cost of smoking-related disease 
in Medicaid patients is estimated to be more than $75 billion which is 
about 15% of all Medicaid expenditures. Many smokers want to quit 
and there are a variety of options available to them. Evidence-based 
tobacco dependence treatments (TDT) include individual, group, 
and telephone counseling, along with seven FDA-approved nicotine 
replacement therapies (NRT; nicotine patch, gum, lozenge, nasal 
spray and inhaler, bupropion (Zyban), and varenicline (Chantix)).2-4 
Despite these options for treatment, Kansas has performed poorly 
compared to national NRT usage since passage of the ACA. In 2013, 
49,000 (35%) of Kansas Medicaid enrollees were smokers, with only 
3% of those using medications.2 Additionally, the rate of NRT utiliza-
tion in Kansas from 2011 - 2013 was 0.05 prescriptions per smoker, 
compared with 0.20 prescriptions per smoker nationally.2 These data 
placed Kansas 48th out of 50 states in terms of the frequency with 
which Medicaid smokers receive NRT. 
 Medicaid smokers often do not get help quitting due to multiple 
barriers including cost of treatments, prior authorization require-
ments, lack of awareness of options amongst Medicaid enrollees 
and physicians, as well as physician time constraints and perceived 
patients’ willingness to quit.5 As of January 2014, the Affordable Care 
Act (ACA) required Medicaid programs to cover smoking cessation 
treatment, including over-the-counter medications.6 Previously iden-
tified barriers, such as cost to the patient of pharmacotherapy and 
insurance company resistance to coverage, are negated partially by 
the Affordable Care Act mandate for Medicaid to cover NRT at no 
cost to the patient. A systematic review of smoking cessation guide-
lines recommended that clinicians should encourage all patients 
interested in quitting to utilize tobacco dependence therapy to aid in 
cessation unless they are light smokers, adolescents, pregnant women, 
or smokeless tobacco users.7
To bridge the gap between expanded Medicaid coverage and utili-
zation of coverage in a practical sense, the process a patient undergoes 
to procure and use cessation treatment must be understood. There 
are many potential pitfalls in the process, including lack of physician 
and patient knowledge of Medicaid coverage, treatment not being 
prescribed, lack of pharmacist knowledge of which National Drug 
Codes cover specific NRT, confusion at the pharmacy regarding spe-
cific product coverage, and patients’ perception of NRT effectiveness 
and willingness to use.5 Indeed, counselors in the tobacco treatment 
service at the University of Kansas Medical Center (KUMC) reported 
that some patients were not getting prescriptions for smoking cessa-
tion medications and others who had received prescriptions for NRT 
were not able to get these prescriptions filled at the pharmacy. To 
better understand this potential problem in the quality of smoking 
cessation services, we assessed current barriers to treatment from a 
patient perspective to identify which of these represent the principal 
barrier or barriers to patients obtaining and utilizing the Medicaid 
smoking cessation benefit and ultimately in quitting smoking.
METHODS
 Participants and Setting. Using the Heron9 system interface to 
the electronic health record, we identified patients 18 years or older 
seen in the KUMC Internal Medicine Clinic between January 1, 2015 
and January 1, 2016 who were identified as smokers.  From this group, 
we selected patients who were enrolled in Kansas Medicaid and 
excluded patients who were deceased or for whom English was not 
their primary language. One or more attempts were made to contact 
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phone, the patient was provided with a brief verbal description of 
the project and provided their assent for participation in a brief tele-
phone survey (Figure 1).
Figure 1. How patients were identified and included or excluded.
Data Collection. Demographic data were captured from the elec-
tronic health record through the HERON interface, including gender, 
race, and age. People who responded to the phone survey were asked 
whether they were interested in quitting smoking, counseled by their 
doctor on the benefit of quitting, interested in using treatment to help 
them quit, prescribed pharmacotherapy, what type of pharmacother-
apy they received, if they filled their prescription, if their prescription 
was filled at no cost, if they used the prescription, and if the prescrip-
tion helped them quit. Data collected via interviews were entered 
into and stored securely using REDCap electronic data capture tools 
hosted at the University of Kansas Medical Center.10 
Data Analysis. The primary outcome was the proportion of 
KUMC Internal Medicine Medicaid enrollees who received phar-
macotherapy for tobacco cessation and were able to utilize the 
Medicaid benefit. Secondary outcomes included the proportion of 
Internal Medicine Medicaid enrollees who were counseled about 
quitting smoking in the last year, the proportion that were prescribed 
pharmacotherapy, the proportion aware of Medicaid coverage of 
pharmacotherapy, and the proportion interested in receiving phar-
macotherapy in the future. All outcomes were calculated as simple 
frequencies. Data analysis was conducted using Microsoft Excel after 
removal of all the protected health information.
 This project was reviewed by the KUMC Institutional Review 
Board and deemed as a quality improvement project designed to 
improve uptake and utilization of smoking cessation pharmacother-
apy.
RESULTS
Prescription and Utilization.  Of the 169 smokers that met the 
inclusion criteria, 62 (37%) responded to the survey. The mean age of 
the survey respondents was 53 years. Approximately half were female 
(52%) and Caucasian (52%), while 45% were African American 
(Table 1). Of the 62 respondents, 41 (66%) were interested in receiv-
ing cessation therapy and 24 (39%) of patients had been prescribed 
NRT. Of the 24 patients prescribed therapy, 20 (83%) filled their pre-
scription at the pharmacy. Of the 20 that filled their prescription,  13 
(65%) took advantage of the Medicaid benefit and filled it at no cost.
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Also, 80% of patients prescribed therapy reported using the therapy 
and 38% of patients reported that the NRT prescribed aided them in 
quitting smoking (Table 2). When patients were asked whether they 
were aware that Kansas Medicaid should cover their prescription 
therapy only 23 (43%) of patients were aware this option existed.
Table 1. Demographics of population studied. 
Male 30 (48%)
Female 32 (52%)
Caucasian 32 (52%)
African American 20 (45%)
Table 2. Results of phone survey (n; %).
Counseled by doctor on quitting 57 (92)
Interested in quitting 47 (76)
Interested in therapy 41 (65)
Prescribed therapy 24 (39)
Filled prescription 20 (32)
Filled prescription at no cost 13 (65)
Used prescription 15 (24)
Prescription aided in quitting 9 (15)
Nicotine Replacement Therapy. The nicotine patch was the 
number one prescribed tobacco cessation therapy representing 15 
out of the 37 (41%) prescribed therapies. Varenicline was prescribed 
to 24% of patients and the nicotine gum was prescribed to 22% of 
patients. The nicotine lozenge was prescribed to only 5% of patients 
and bupropion was prescribed to only 2.7% of patients. Another 2.7% 
of patients were prescribed therapy but were unsure of the specific 
therapy their doctor recommended (Figure 2). The majority of pre-
scriptions for tobacco cessation therapy were for the nicotine patch 
followed by varenicline and the nicotine gum; together these three 
represent 90% of total prescribed therapies. There were a total of 
37 prescriptions for tobacco therapy given to a total of 24 patients as 
some patients were prescribed multiple therapies. 
Pharmacy Coverage. There was variation between pharma-
cies on whether prescriptions were filled at no out of pocket cost to 
patients. Of the 37 prescriptions that were attempted to be filled, 20 
(54%) were filled at no cost to the patient thus honoring the Med-
icaid benefit. Out of the five patients who filled their prescription 
at Walgreen’s, four (80%) took advantage of the Medicaid benefit 
and paid no out of pocket cost.  This is compared to one of the five 
patients (20%) who went to Walmart to take advantage of the Med-
icaid benefit. All three patients who filled their prescription at CVS 
took advantage of the benefit.
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Figure 2. Types of pharmacotherapy prescribed. 
DISCUSSION
 Three main barriers existed for Medicaid patients interested in 
smoking cessation from receiving treatment. First, physicians did not 
prescribe therapy to all of their patients who expressed interest in 
cessation. Of the 41 patients interested in receiving therapy, only 24 
(58%) were prescribed NRT. This is consistent with previous statistics 
on low prescribing practices amongst Kansas physicians to Medicaid 
patients.2 Physician lack of prescribing represents the main barrier to 
patients interested in quitting, however, when physicians prescribe 
therapy, the nicotine patch and gum, along with varenicline, are the 
most frequent choices for therapy. Further studies will be needed to 
elucidate whether the low prevalence of prescribing practices is due 
to physician lack of knowledge of Medicaid NRT coverage or if physi-
cian time constraint due to the many underserved areas in Kansas 
accounts for this statistic.
 Another barrier to patients receiving therapy is the fact that only 
43% of patients who identify as smokers were aware that Medicaid 
should cover their NRT. The majority of Medicaid patients were dis-
advantaged socioeconomically and already struggling with the burden 
of high medical costs. This lack of awareness that therapy should be 
covered presents another deterrent to those interested in quitting. 
Increased physician awareness that their patients are interested in 
quitting and that Medicaid should cover NRT will foster more conver-
sations with patients about smoking cessation, leading to more people 
quitting.
 The third barrier was NRT filling by pharmacies and whether 
patients were able to take advantage of the Medicaid benefit. Accord-
ing to our survey, the rate of prescriptions that were filled at no cost to 
the patient was 54% with evidence that different pharmacies varied 
on whether they required patients to pay. A comprehensive assess-
ment of pharmacy filling practices identifying where patients should 
have NRT filled would reduce patient costs and enable them to use the 
full benefit of Medicaid available to them. 
 Utilizing Medicaid’s policy on tobacco cessation would cut costs 
to the program, as well as decrease morbidity and mortality to its 
enrollees. A cost-benefit study in Massachusetts analyzed the finan-
cial cost of smoking cessation per patient compared to the reduced 
financial cost of hospital admissions that smoking cessation pro-
vides to the state Medicaid program.8 Every $183 spent per patient 
on tobacco cessation averted an average of $571 per patient on hos-
pital admissions, equivalent to $2.21 saved for each $1 spent. This 
shows that states investing in cessation therapy avoid long term costs 
from increased patient morbidity and hospitalizations incurred from 
smoking. While the reduced cost to the system is one benefit, more 
importantly, patients who quit live healthier lives with less disease 
burden.1  
 There are several limitations to this study. First, surveys were 
self-reported by patients ,which required them to remember a con-
versation with their provider that could have been a year earlier. 
Also, patients were sampled from one tertiary care facility in Kansas 
which may not be representative of all Medicaid patients across the 
state. The response rate was 37%, which may not reflect the entire 
population; however, the demographics were similar between those 
who responded to the phone interview and the study population as a 
whole. 
 The results of the project have strong potential to direct future 
care of Medicaid enrollees who smoke. This information helps pro-
viders understand the state of cessation therapy being prescribed to 
this patient population in Kansas and inform future improvements in 
prescribing practices. It is also important for Medicaid patients to be 
aware that therapy should be covered, they should try to fill their pre-
scription at certain pharmacies, and try multiple pharmacies before 
paying out of pocket. Some of the specific future interventions could 
include patient education through pamphlets at clinics, increased 
physician awareness of coverage and patient interest, and modifica-
tions of the electronic medical record to facilitate conversations in the 
clinic about smoking cessation therapy.
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